Adrenal atrophy overview

Revision as of 04:01, 5 February 2022 by Maryam Hadipour (talk | contribs)
Jump to navigation Jump to search

Adrenal atrophy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenal atrophy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Adrenal atrophy overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenal atrophy overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenal atrophy overview

CDC on Adrenal atrophy overview

Adrenal atrophy overview in the news

Blogs on Adrenal atrophy overview

Directions to Hospitals Treating Adrenal atrophy

Risk calculators and risk factors for Adrenal atrophy overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Adrenal glands, also known as suprarenal glands, are small, triangular-shaped glands located on top of both kidneys. They produce hormones that help regulate your metabolism, immune system, blood pressure, response to stress and other essential functions. Adrenal atrophy may be caused by loss of ACTH and trophic support of the adrenal cortex (due to exogenous corticosteroid overuse) or direct damage to the tissue caused by infections (TB, CMV, histoplasmosis, paracoccidioidomycosis), vascular impairments (hemorrhage from sepsis, adrenal vein thrombosis, HIT), deposition disease (hemochromatosis, amyloidosis, sarcoidosis), or drugs (azole anti-fungals, etomidate, rifampin, anticonvulsants) or cytotoxic agents such as mitotane. The onset of clinical manifestations is dependent to the etiology of the atrophy. However, the symptoms of the adrenal atrophy usually develop in patient’s 30s to 50s and in their 60s in the case of secondary adrenal atrophy. Common complications of the adrenal atrophy and its malfunction include hypoglycemia, dehydration, weight loss, and disorientation. Prognosis is generally poor, due to the irreversibility of atrophy and the one out of 200 patients with adrenal atrophy die each year due to the adrenal crisis. As the disease consists of the irreversible atrophy of the adrenal gland treatment of the adrenal atrophy is a conservative treatment, including hormone replacement therapy and managing the adrenal crisis state.

References

Template:WH Template:WS